Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

According to the latest study from BCC Research, "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic ...

My mother has been diagnosed with breast cancer, and I’m helping with her medical appointments. Her oncologist says she needs ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...